Clinical Trial: Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06809374) titled 'Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer' on Jan. 30.

Brief Summary: Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.

Study Start Date: Jan. 01, 2015

Study Type: OBSERVATIONAL

Condition: Pancreatic Cancer Resectable

Intervention: DRUG: gemcitabine

neoadjuvant therapy for resectable pancreatic cancer using gemcitabine +S1 or gemcitabine + nab-Paxitaxel

Recruitment Status: COMPLETED

Sponsor: Kochi University

Information provided by (Responsible Party): Takehiro Okabayashi, Kochi Univer...